Teva Pharmaceutical Industries has announced that the FDA has granted tentative approval for the company's abbreviated new drug application to market rizatriptan benzoate tablets.
Subscribe to our email newsletter
Rizatriptan benzoate is a generic version of Merck’s migraine pain treatment Maxalt tablets, equivalent to 5mg and 10mg base.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.